Entacapone and meclofenamate (MA) 2, approved by the U.S. Food and Drug Administration (FDA) as FTO inhibitors, have been demonstrated to hold the efficacy in improving chemotherapy drug sensitivity and inhibiting tumor progression in multiple cancer types [94, 95]. The gene discussed is FTO; the disease is neoplasm.